These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 19285261)
1. The role of the endocannabinoid system in liver diseases. Caraceni P; Domenicali M; Giannone F; Bernardi M Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):65-77. PubMed ID: 19285261 [TBL] [Abstract][Full Text] [Related]
2. The endocannabinoid system and liver diseases. Caraceni P; Domenicali M; Bernardi M J Neuroendocrinol; 2008 May; 20 Suppl 1():47-52. PubMed ID: 18426499 [TBL] [Abstract][Full Text] [Related]
3. [The endocannabinoid system as a novel target for the treatment of liver fibrosis]. Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Hezode C; Mallat A; Lotersztajn S Pathol Biol (Paris); 2008 Feb; 56(1):36-8. PubMed ID: 17412522 [TBL] [Abstract][Full Text] [Related]
4. Role of cannabinoids in the development of fatty liver (steatosis). Purohit V; Rapaka R; Shurtleff D AAPS J; 2010 Jun; 12(2):233-7. PubMed ID: 20204561 [TBL] [Abstract][Full Text] [Related]
5. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Mallat A; Lotersztajn S Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G9-G12. PubMed ID: 17975129 [TBL] [Abstract][Full Text] [Related]
7. The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives. Baldassarre M; Giannone FA; Napoli L; Tovoli A; Ricci CS; Tufoni M; Caraceni P Liver Int; 2013 Oct; 33(9):1298-308. PubMed ID: 23890208 [TBL] [Abstract][Full Text] [Related]
8. Endocannabinoids as novel mediators of liver diseases. Mallat A; Lotersztajn S J Endocrinol Invest; 2006; 29(3 Suppl):58-65. PubMed ID: 16751709 [TBL] [Abstract][Full Text] [Related]
9. Endocannabinoids, CB1 receptors, and liver disease: hitting more than one bird with the same stone. Kunos G; Gao B Gastroenterology; 2008 Feb; 134(2):622-5. PubMed ID: 18242226 [No Abstract] [Full Text] [Related]
10. Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis. Mallat A; Lotersztajn S Diabetes Metab; 2008 Dec; 34(6 Pt 2):680-4. PubMed ID: 19195630 [TBL] [Abstract][Full Text] [Related]
11. Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors. Hungund BL; Basavarajappa BS Ann N Y Acad Sci; 2004 Oct; 1025():515-27. PubMed ID: 15542757 [TBL] [Abstract][Full Text] [Related]
12. Endocannabinoids in liver disease. Tam J; Liu J; Mukhopadhyay B; Cinar R; Godlewski G; Kunos G Hepatology; 2011 Jan; 53(1):346-55. PubMed ID: 21254182 [TBL] [Abstract][Full Text] [Related]
13. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Siegmund SV; Schwabe RF Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G357-62. PubMed ID: 18006606 [TBL] [Abstract][Full Text] [Related]
14. The role of the CB1 receptor in the regulation of sleep. Murillo-Rodríguez E Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1420-7. PubMed ID: 18514375 [TBL] [Abstract][Full Text] [Related]
15. Role of cannabinoids in chronic liver diseases. Parfieniuk A; Flisiak R World J Gastroenterol; 2008 Oct; 14(40):6109-14. PubMed ID: 18985799 [TBL] [Abstract][Full Text] [Related]
16. The cannabinoid system and immune modulation. Klein TW; Newton C; Larsen K; Lu L; Perkins I; Nong L; Friedman H J Leukoc Biol; 2003 Oct; 74(4):486-96. PubMed ID: 12960289 [TBL] [Abstract][Full Text] [Related]
17. Endocannabinoids and their role in fatty liver disease. Mallat A; Lotersztajn S Dig Dis; 2010; 28(1):261-6. PubMed ID: 20460921 [TBL] [Abstract][Full Text] [Related]
18. The implication of CNR1 gene's polymorphisms in the modulation of endocannabinoid system effects. Dinu IR; Popa S; Bîcu M; Moţa E; Moţa M Rom J Intern Med; 2009; 47(1):9-18. PubMed ID: 19886064 [TBL] [Abstract][Full Text] [Related]